Skip to Main Content

Paper Details

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
128
2019
Cancer, EGFR, ERBB2, ERBB2 Mutations, ERBB2 exon 20, ERBB2 exon 20-mutant, ERBB2 mutational, HER2, HER2 mutant, HER2 mutants, Pan, Poziotinib, T-DM1, cancers, mutational hotspots, patients, poziotinib, tumor
Author NameAffiliation
Huandong SunMD Anderson Cancer Center
Lixia DiaoMD Anderson Cancer Center
Funda Meric-BernstamMD Anderson Cancer Center
Mark J RoutbortMD Anderson Cancer Center
Vincent A MillerFoundation Medicine
  • 1 - 5

Datasets

Release 1.2